ESR1 and breast neoplasm: In breast cancer, PARP-1 up-regulation has been associated with decreased survival [14] and triple-negative (TN) cancers (breast tumours in which estrogen receptor [ER], progesterone receptor [PR] and human epidermal growth factor receptor 2 [HER2] are not expressed) [15].